Viral Macrophage-Inflammatory Protein
Source Viral Macrophage-Inflammatory Protein at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Viral macrophage‑inflammatory protein‑II (vMIP‑II) is a small chemokine encoded by human herpesvirus‑8. It acts as a broad‑spectrum modulator of chemokine receptors, capable of both antagonising many inflammatory pathways and agonising select receptors such as CCR8. Pre‑clinical studies have used vMIP‑II to dampen leukocyte recruitment in organ transplantation, reduce brain infarct size after stroke, and enhance the therapeutic targeting of engineered extracellular vesicles for viral myocarditis.
Mechanism of Action
vMIP‑II mimics host CC‑type chemokines but binds a wide array of chemokine receptors across all four classes (CC, C, CXC, CX3C). It blocks signalling at receptors such as CCR1, CCR2, CCR5, CXCR3 and the atypical receptor XCR1/GPR5, preventing leukocyte chemotaxis. In contrast, it acts as an agonist at CCR8, selectively attracting Th2‑polarised T cells. By inhibiting chemokine‑driven recruitment and altering receptor activation profiles, vMIP‑II reduces inflammatory cell influx and can re‑programme macrophage phenotypes from pro‑inflammatory (M1) to reparative (M2).
What the Research Shows
Animal investigations demonstrate that daily vMIP‑II administration (15–100 µg) improves acute renal allograft pathology in rats by lowering leukocyte adhesion and restoring peritubular capillary flow. In a rat model of focal cerebral ischemia, intracerebroventricular vMIP‑II reduced infarct volume in a dose‑dependent manner, suggesting neuroprotective effects via chemokine receptor blockade. A 2024 study engineered M2‑derived extracellular vesicles to display a cardiac‑targeting peptide, platelet membrane, and vMIP‑II; intravenous delivery to mice with viral myocarditis enhanced vesicle homing, promoted M1‑to‑M2 macrophage conversion, and improved cardiac repair. Biochemical work identified vMIP‑II as a potent antagonist of the XCR1 (GPR5) receptor, extending its inhibitory spectrum to C‑class chemokines. A review summarises its dual agonist/antagonist profile and highlights its utility as a research tool for dissecting chemokine networks.
Reported Benefits
Pre‑clinical data suggest that vMIP‑II can attenuate acute inflammatory injury in transplanted kidneys, limit cerebral infarct size after stroke, and boost the efficacy of targeted immunomodulatory therapies for viral myocarditis. Its broad receptor antagonism reduces leukocyte recruitment, while selective CCR8 agonism may help shift immune responses toward a Th2 phenotype, potentially aiding tissue repair. Engineered delivery platforms incorporating vMIP‑II have shown enhanced cardiac targeting and macrophage re‑programming in mouse models.
Limitations of the Evidence
Evidence for vMIP‑II is confined to animal experiments and in‑vitro receptor studies; no human clinical trials have been reported. The dual agonist/antagonist nature may produce unpredictable immune effects in different tissues. Dosing regimens, pharmacokinetics, and long‑term safety remain undefined, and the protein’s viral origin raises concerns about immunogenicity. Translation to clinical use will require extensive safety and efficacy evaluation.
Safety Considerations
The cited studies do not report adverse events associated with vMIP‑II administration in rodents or mice, but the absence of systematic toxicity data limits conclusions about safety. Potential risks include unintended modulation of chemokine pathways, possible promotion of Th2‑biased immunity, and immunogenic reactions due to its viral origin. Until comprehensive pre‑clinical toxicology and immunogenicity assessments are performed, caution is warranted for any experimental use.
How It Is Administered
vMIP‑II has been delivered intravenously in mouse studies and intracerebroventricularly in rat brain experiments. Reported dosing in rats ranged from two 15 µg injections to 100 µg per day for a week in transplantation models. In engineered extracellular vesicle formulations, the protein is incorporated into vesicle membranes and administered via systemic intravenous injection. Formulations are protein‑based, typically prepared in sterile aqueous solutions for injection.
Routes of Administration
No administration routes recorded yet.
Goals & Uses
No goal associations recorded yet.
Contraindications
No contraindications recorded yet.
Adverse Effects
No adverse effects recorded yet.
Drug Interactions
No drug interactions recorded yet.
Population Constraints
No population constraints recorded yet.
Regulatory Status
No regulatory status recorded yet.
Evidence & Sources
- Journal ArticleLowBedke J, et al.2010-01-01T00:00:00.000000Z
- Journal ArticleLowPei W, et al.2024-01-01T00:00:00.000000Z
- Journal ArticleModerateSzpakowska M, Chevigné A2016-01-01T00:00:00.000000Z
- Journal ArticleLowShan L, et al.2000-01-01T00:00:00.000000Z
- Journal ArticleLowSozzani S, et al.1998-01-01T00:00:00.000000Z
- Journal ArticleModerateMinami M, Satoh M2003-01-01T00:00:00.000000Z
Frequently Asked Questions
What type of molecule is vMIP‑II?
vMIP‑II is a viral chemokine protein encoded by human herpesvirus‑8. It mimics host chemokines but can bind many chemokine receptors, acting as both an antagonist and, for CCR8, an agonist.
Has vMIP‑II been tested in humans?
No human clinical trials are cited. All reported effects come from animal models (rats, mice) and in‑vitro receptor studies, so its safety and efficacy in people are still unknown.
How does vMIP‑II reduce inflammation?
By blocking chemokine receptors that guide leukocyte migration, vMIP‑II prevents immune cells from entering inflamed tissues. It also shifts macrophages from a pro‑inflammatory (M1) to a reparative (M2) state when delivered via engineered vesicles.
What are the main safety concerns?
Safety data are limited; potential concerns include off‑target immune modulation, promotion of Th2‑type responses, and immune reactions to a viral protein. Formal toxicology studies have not yet been published.
Can vMIP‑II be used as a drug today?
No. vMIP‑II is an experimental research tool with no regulatory approval for therapeutic use. Its development is still at the pre‑clinical stage.
What is Viral Macrophage-Inflammatory Protein?
Viral macrophage‑inflammatory protein‑II (vMIP‑II) is a small chemokine encoded by human herpesvirus‑8. It acts as a broad‑spectrum modulator of chemokine receptors, capable of both antagonising many inflammatory pathways and agonising select receptors such as CCR8. Pre‑clinical studies have used vMIP‑II to dampen leukocyte recruitment in organ transplantation, reduce brain infarct size after stroke, and enhance the therapeutic targeting of engineered extracellular vesicles for viral myocarditis.